Ola-F Tablet is a combination pharmaceutical formulation containing Fluoxetine 20 mg and Olanzapine 5 mg, indicated for the treatment of depressive disorders, particularly major depressive disorder with psychotic features and treatment-resistant depression. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), acts by increasing serotonin levels in the central nervous system, thereby improving mood, anxiety, and overall emotional state. Olanzapine, an atypical antipsychotic, exerts its therapeutic effects by antagonizing dopamine and serotonin receptors, which helps in managing psychotic symptoms and mood stabilization. The synergistic action of these two agents provides enhanced efficacy in patients who have not responded adequately to monotherapy. Ola-F Tablet should be administered under strict medical supervision, with dosage tailored to individual patient needs and clinical response. Common adverse effects may include weight gain, sedation, dry mouth, dizziness, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiovascular disease, diabetes, or seizures. Regular monitoring of metabolic parameters and mental status is recommended during treatment. Ola-F Tablet is contraindicated in patients with hypersensitivity to its components and should be used cautiously during pregnancy and lactation. This combination therapy offers a valuable option for complex depressive disorders requiring both antidepressant and antipsychotic intervention.